Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1966]

Teclistamab plus talquetamab targeting BCMA and GPRC5D shows promise in RRMM

Dr Yael Cohen - Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel

Teclistamab plus talquetamab targeting BCMA and GPRC5D shows promise in RRMM ( Dr Yael Cohen - Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel )

Talquetamab plus daratumumab for RRMM: TRIMM-2 update

Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville...

Talquetamab plus daratumumab for RRMM: TRIMM-2 update ( Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, USA )

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment...

Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer ( Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan )

The current status of multiple myeloma diagnosis and treatment

Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina

The current status of multiple myeloma diagnosis and treatment ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )

Choosing cancer medicines wisely in Africa

Dr Harrison Chuwa - Aga Khan Hospital, Dar es Salaam, Tanzania

Choosing cancer medicines wisely in Africa ( Dr Harrison Chuwa - Aga Khan Hospital, Dar es Salaam, Tanzania )

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?

Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru

Targeting BRAF V600E in metastatic colorectal cancer: where are we today? ( Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru )

Adding new vaccine type to leading immunotherapy dramatically reduces melanoma...

Dr Jeffrey Weber - NYU Langone’s Perlmutter Cancer Center, Newyork, USA

Adding new vaccine type to leading immunotherapy dramatically reduces melanoma recurrence ( Dr Jeffrey Weber - NYU Langone’s Perlmutter Cancer Center, Newyork, USA )

Encouraging safety and efficacy for REGN5459, a BCMA×CD3 bispecific antibody...

Dr Attaya Suvannasankha - Indiana University Melvin and Bren Simon Cancer...

Encouraging safety and efficacy for REGN5459, a BCMA×CD3 bispecific antibody with low CD3 affinity, in patients with RRMM ( Dr Attaya Suvannasankha - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA )

Choosing Wisely in neoadjuvant treatment for different cancers in the...

Dr Priscilla Caguioa - St Luke's Medical Center, Manila, Philippines

Choosing Wisely in neoadjuvant treatment for different cancers in the Philippines ( Dr Priscilla Caguioa - St Luke's Medical Center, Manila, Philippines )

A multidisciplinary team approach to cancer care in the Philippines

Dr Arnold John Uson - Perpetual Succour Hospital of Cebu, Cebu, Philippines

A multidisciplinary team approach to cancer care in the Philippines ( Dr Arnold John Uson - Perpetual Succour Hospital of Cebu, Cebu, Philippines )

Neoadjuvant nivolumab plus chemotherapy continues to provide long-term clinical...

Prof Nicolas Girard - Institut Curie, Paris, France

Neoadjuvant nivolumab plus chemotherapy continues to provide long-term clinical benefit in patients with resectable NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Four chemo cycles given with durvalumab and tremelimumab optimise response and...

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )

More from ecancer